دورية أكاديمية
أعرض في EDS

MEK Inhibition Induces Canonical WNT Signaling through YAP in KRAS Mutated HCT-15 Cells, and a Cancer Preventive FOXO3/FOXM1 Ratio in Combination with TNKS Inhibition.

التفاصيل البيبلوغرافية
العنوان: MEK Inhibition Induces Canonical WNT Signaling through YAP in KRAS Mutated HCT-15 Cells, and a Cancer Preventive FOXO3/FOXM1 Ratio in Combination with TNKS Inhibition.
المؤلفون: Solberg NT; Unit for Cell Signaling, Department of Immunology and Transfusion Medicine, Oslo University Hospital, 0372 Oslo, Norway. nina.therese.solberg@rr-research.no.; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, PO Box 1112 Blindern, 0317 Oslo, Norway. nina.therese.solberg@rr-research.no., Melheim M; Unit for Cell Signaling, Department of Immunology and Transfusion Medicine, Oslo University Hospital, 0372 Oslo, Norway. maria.melheim@rr-research.no.; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, PO Box 1112 Blindern, 0317 Oslo, Norway. maria.melheim@rr-research.no., Strand MF; Department of Health Sciences, Kristiania University College, PB 1190 Sentrum, 0107 Oslo, Norway. martinfrank.strand@kristiania.no., Olsen PA; Unit for Cell Signaling, Department of Immunology and Transfusion Medicine, Oslo University Hospital, 0372 Oslo, Norway. petter.angell.olsen@rr-research.no.; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, PO Box 1112 Blindern, 0317 Oslo, Norway. petter.angell.olsen@rr-research.no., Krauss S; Unit for Cell Signaling, Department of Immunology and Transfusion Medicine, Oslo University Hospital, 0372 Oslo, Norway. Stefan.krauss@rr-research.no.; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, PO Box 1112 Blindern, 0317 Oslo, Norway. Stefan.krauss@rr-research.no.
المصدر: Cancers [Cancers (Basel)] 2019 Feb 01; Vol. 11 (2). Date of Electronic Publication: 2019 Feb 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: The majority of colorectal cancers are induced by subsequent mutations in APC and KRAS genes leading to aberrant activation of both canonical WNT and RAS signaling. However, due to induction of feedback rescue mechanisms some cancers do not respond well to targeted inhibitor treatments. In this study we show that the APC and KRAS mutant human colorectal cancer cell line HCT-15 induces canonical WNT signaling through YAP in a MEK dependent mechanism. This inductive loop is disrupted with combined tankyrase (TNKS) and MEK inhibition. RNA sequencing analysis suggests that combined TNKS/MEK inhibition induces metabolic stress responses in HCT-15 cells promoting a positive FOXO3/FOXM1 ratio to reduce antioxidative and cryoprotective systems.
References: EMBO J. 1999 Oct 1;18(19):5310-20. (PMID: 10508164)
Mol Cell Biol. 2002 Feb;22(4):1172-83. (PMID: 11809808)
Mol Cell Biol. 2002 Feb;22(4):1184-93. (PMID: 11809809)
Oncogene. 2006 Dec 4;25(57):7482-91. (PMID: 17143292)
Cell. 2009 May 15;137(4):623-34. (PMID: 19450512)
Nature. 2009 Oct 1;461(7264):614-20. (PMID: 19759537)
J Exp Clin Cancer Res. 2010 Jun 22;29:81. (PMID: 20569498)
Annu Rev Pathol. 2011;6:479-507. (PMID: 21090969)
Cancer Res. 2011 Jan 1;71(1):197-205. (PMID: 21199802)
Oncogene. 2012 Apr 5;31(14):1845-58. (PMID: 21860419)
Cancer Cell. 2011 Oct 18;20(4):427-42. (PMID: 22014570)
Cancer Res. 2012 Jan 1;72(1):210-9. (PMID: 22084396)
Cancer Res. 2012 Jun 1;72(11):2822-32. (PMID: 22440753)
Sci Signal. 2012 Apr 10;5(219):ra30. (PMID: 22494971)
Cancer Res. 2012 Aug 15;72(16):4154-64. (PMID: 22738915)
Mol Cell Biol. 2012 Oct;32(19):3838-50. (PMID: 22826436)
Cell Cycle. 2012 Oct 15;11(20):3724-30. (PMID: 22895053)
Cell Death Dis. 2012 Dec 13;3:e442. (PMID: 23235459)
Cell. 2012 Dec 21;151(7):1457-73. (PMID: 23245941)
Annu Rev Pharmacol Toxicol. 2013;53:401-26. (PMID: 23294312)
J Med Chem. 2013 Apr 11;56(7):3012-23. (PMID: 23473363)
Cancer Res. 2013 May 15;73(10):3132-44. (PMID: 23539443)
Nat Rev Cancer. 2013 Jul;13(7):482-95. (PMID: 23792361)
BMC Cancer. 2013 Jul 03;13:327. (PMID: 23819460)
Stem Cell Res. 2014 Jan;12(1):119-31. (PMID: 24185179)
Zhonghua Zhong Liu Za Zhi. 2013 Aug;35(8):572-8. (PMID: 24314213)
J Natl Cancer Inst. 2014 Feb;106(2):djt373. (PMID: 24491301)
Cancer Res. 2014 Jun 15;74(12):3294-305. (PMID: 24747911)
Cancer Res. 2014 Jun 15;74(12):3238-47. (PMID: 24755471)
Cell. 2014 Jul 3;158(1):185-197. (PMID: 24954535)
Cell. 2014 Jul 3;158(1):157-70. (PMID: 24976009)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Nat Genet. 2015 Mar;47(3):250-6. (PMID: 25665005)
Oncotarget. 2015 Aug 21;6(24):20661-71. (PMID: 25970782)
Genes Dev. 2015 Jul 15;29(14):1493-506. (PMID: 26193883)
Cell. 2015 Aug 13;162(4):780-94. (PMID: 26276632)
Oncotarget. 2015 Sep 29;6(29):27688-99. (PMID: 26299613)
PLoS Genet. 2016 Mar 15;12(3):e1005931. (PMID: 26978032)
Mol Cell Oncol. 2015 Apr 27;3(1):e1021441. (PMID: 27308535)
Development. 2016 Sep 1;143(17):3128-42. (PMID: 27578179)
Cell Rep. 2017 Feb 7;18(6):1543-1557. (PMID: 28178529)
Sci Rep. 2017 Apr 05;7:45951. (PMID: 28378765)
Theranostics. 2017 Feb 27;7(5):1100-1113. (PMID: 28435451)
Mol Oncol. 2017 Sep;11(9):1273-1287. (PMID: 28632938)
Int J Mol Sci. 2017 Jul 25;18(8):null. (PMID: 28757546)
PLoS One. 2017 Sep 6;12(9):e0184068. (PMID: 28877210)
Semin Cancer Biol. 2018 Jun;50:77-89. (PMID: 29180117)
Mol Cancer Res. 2018 Mar;16(3):543-553. (PMID: 29222171)
Free Radic Biol Med. 2018 Feb 1;115:447-457. (PMID: 29248722)
Oncotarget. 2017 Nov 27;8(65):109301-109318. (PMID: 29312609)
NPJ Precis Oncol. 2018 Feb 20;2(1):5. (PMID: 29872723)
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3046-50. (PMID: 7708772)
Cancer Res. 1994 Jun 1;54(11):3011-20. (PMID: 8187091)
Bull Cancer. 1998 Nov;85(11):925-8. (PMID: 9951419)
معلومات مُعتمدة: 262613 Norges Forskningsråd
فهرسة مساهمة: Keywords: FOXM1; FOXO3; MEK; RNAseq; WNT; YAP; colorectal cancer; inhibition; tankyrase
تواريخ الأحداث: Date Created: 20190206 Latest Revision: 20201001
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6406699
DOI: 10.3390/cancers11020164
PMID: 30717152
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers11020164